drugset / Trial / NCT03490760
Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas
NaSingle-groupOpen-labelTreatment
Summary
This is a single-institution, single-arm phase II trial of Durvalumab combined with Radiation Therapy (RT) for metastatic pancreatic cancer patients who have progressed through first-line chemotherapy.
Timeline
- Start
- 2018-11-09
- Primary completion
- 2020-07-09
- Completion
- 2020-07-09
Outcome
Outcome not reported
Stopped (Enrollment): “Slow/poor enrollment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | 20 mg/m2 | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | 1500 mg | Intravenous |